Syndax Pharmaceuticals financials
$18.24+2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M | $64.9M | $68.7M | $45.9M | $38.0M | $20.0M | $7.7M | $12.5M | $3.5M | $0.00 | $0.00 | $0.00 |
| Gross profit | $69.6M | $62.2M | $66.0M | $43.8M | $36.7M | $19.2M | $6.9M | $12.5M | $3.5M | $0.00 | $0.00 | $0.00 |
| Gross margin | 95.6% | 95.9% | 96.1% | 95.4% | 96.6% | 95.6% | 89.2% | 100.0% | 100.0% | — | — | — |
| Operating income | -$40.0M | -$46.0M | -$38.4M | -$65.7M | -$69.4M | -$91.8M | -$96.4M | -$89.6M | -$74.2M | -$79.5M | -$77.9M | -$56.4M |
| Net income | -$49.4M | -$42.7M | -$68.0M | -$60.7M | -$71.8M | -$84.8M | -$94.2M | -$84.1M | -$68.1M | -$72.4M | -$72.5M | -$51.1M |
| Net margin | −67.8% | −65.8% | −99.0% | −132.4% | −189.3% | −423.3% | −1226.2% | −673.0% | −1944.7% | — | — | — |
| Diluted EPS | $-0.55 | $-0.48 | $-0.78 | $-0.70 | $-0.83 | $-0.98 | $-1.09 | $-0.98 | $-0.80 | $-0.85 | $-1.00 | $-0.73 |
| EBITDA | -$40.0M | -$46.0M | -$38.4M | -$65.7M | -$69.4M | -$91.6M | -$96.4M | -$89.6M | -$74.2M | -$79.5M | -$77.9M | -$56.4M |
| Operating cash flow | -$30.3M | -$50.3M | -$69.5M | $0.00 | -$87.8M | -$95.2M | -$57.4M | $0.00 | $0.00 | -$83.5M | -$41.3M | -$44.7M |
| Free cash flow | -$30.3M | -$50.3M | -$69.7M | $0.00 | -$87.8M | -$95.2M | -$57.4M | $0.00 | $0.00 | -$83.5M | -$41.3M | -$44.7M |
| Diluted shares | 89.0M | 88.3M | 87.4M | 86.6M | 86.3M | 86.2M | 86.6M | 85.4M | 85.3M | 85.2M | 72.5M | 69.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $336.5M | $130.9M | $134.9M | $116.8M | $108.6M | $154.0M |
| Short-term investments | $211.4M | $221.2M | $259.1M | $319.2M | $346.6M | $358.2M |
| Total debt | $588.9M | $908.0K | $345.0M | $345.1M | $345.2M | $15.6M |
| Total assets | $703.7M | $472.7M | $529.7M | $551.8M | $596.1M | $640.7M |
| Total liabilities | $688.6M | $431.0M | $465.1M | $436.4M | $438.7M | $425.6M |
| Shareholders' equity | $15.1M | $41.6M | $64.6M | $115.4M | $157.4M | $215.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology